Skip to main content
Top
Published in: Modern Rheumatology 1/2008

01-02-2008 | Case Report

Severe airflow limitation in two patients with systemic lupus erythematosus: effect of inhalation of anticholinergics

Authors: Kimito Kawahata, Masao Yamaguchi, Hiroko Kanda, Akiko Komiya, Ryoichi Tanaka, Makoto Dohi, Yoshikata Misaki, Kazuhiko Yamamoto

Published in: Modern Rheumatology | Issue 1/2008

Login to get access

Abstract

Airway involvement clinically presenting as dyspnea and an obstructive ventilatory defect is a rare but clinically important complication in systemic lupus erythematosus (SLE), since the airway manifestation is often progressive and resistant to systemic immunosuppressive therapy. Here we report two SLE patients with slowly progressive airflow limitation, which was clinically thought to be bronchiolitis obliterans. Both patients showed obvious improvement after inhalation of anticholinergics was started. Because anticholinergics are highly safe and never immunosuppressive, inhalation of these drugs might be useful in the therapeutic strategies for airflow limitation accompanying SLE or other collagen diseases.
Literature
1.
go back to reference Orens JB, Martinez FJ, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 1994;20:159–93.PubMed Orens JB, Martinez FJ, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 1994;20:159–93.PubMed
2.
go back to reference D’Cruz, D, Khamashta MA, Hughes G. Pulmonary manifestations of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Duboi’s lupus erythematosus. 7th ed. Lippincott Williams & Wilkins; 2007. p. 678–99. D’Cruz, D, Khamashta MA, Hughes G. Pulmonary manifestations of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Duboi’s lupus erythematosus. 7th ed. Lippincott Williams & Wilkins; 2007. p. 678–99.
3.
go back to reference Costello RW, Fryer AD. Cholinergic mechanisms in asthma. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, editors. Asthma. Lippincott-Raven Publishers; 1997. pp. 965–84. Costello RW, Fryer AD. Cholinergic mechanisms in asthma. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, editors. Asthma. Lippincott-Raven Publishers; 1997. pp. 965–84.
4.
5.
go back to reference Katzenstein AL, Myers JL, Prophet WD, Corley LS 3rd, Shin MS. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol. 1986;10:373–81.PubMedCrossRef Katzenstein AL, Myers JL, Prophet WD, Corley LS 3rd, Shin MS. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol. 1986;10:373–81.PubMedCrossRef
6.
go back to reference Godeau B, Cormier C, Menkes CJ. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Ann Rheum Dis. 1991;50:956–8.PubMedCrossRef Godeau B, Cormier C, Menkes CJ. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Ann Rheum Dis. 1991;50:956–8.PubMedCrossRef
7.
go back to reference Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22:1007–18.PubMed Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22:1007–18.PubMed
8.
go back to reference Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med. 2002;166:440–4.PubMedCrossRef Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med. 2002;166:440–4.PubMedCrossRef
9.
go back to reference Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271–81.PubMedCrossRef Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271–81.PubMedCrossRef
10.
go back to reference Weber F, Prior C, Kowald E, Schmuth M, Sepp N. Cyclophosphamide therapy is effective for bronchiolitis obliterans occurring as a late manifestation of lupus erythematosus. Br J Dermatol. 2000;143:453–5.PubMedCrossRef Weber F, Prior C, Kowald E, Schmuth M, Sepp N. Cyclophosphamide therapy is effective for bronchiolitis obliterans occurring as a late manifestation of lupus erythematosus. Br J Dermatol. 2000;143:453–5.PubMedCrossRef
11.
go back to reference Reilly JJ Jr. Chronic lung transplant rejection: bronchiolitis obliterans. UpToDate 2006. Reilly JJ Jr. Chronic lung transplant rejection: bronchiolitis obliterans. UpToDate 2006.
12.
go back to reference Matsuyama W, Yamamoto M, Machida K, Oonakahara K, Watanabe M, Higashimoto I, Osame M, Arimura K. A case of bronchiolitis obliterans syndrome successfully treated by Tiotropium bromide (in Japanese). Nihon Kokyuki Gakkai Zasshi. 2006;44:404–9.PubMed Matsuyama W, Yamamoto M, Machida K, Oonakahara K, Watanabe M, Higashimoto I, Osame M, Arimura K. A case of bronchiolitis obliterans syndrome successfully treated by Tiotropium bromide (in Japanese). Nihon Kokyuki Gakkai Zasshi. 2006;44:404–9.PubMed
13.
go back to reference Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pharmacological treatment: bronchodilators. 2003, NIH pp. 67–71. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pharmacological treatment: bronchodilators. 2003, NIH pp. 67–71.
Metadata
Title
Severe airflow limitation in two patients with systemic lupus erythematosus: effect of inhalation of anticholinergics
Authors
Kimito Kawahata
Masao Yamaguchi
Hiroko Kanda
Akiko Komiya
Ryoichi Tanaka
Makoto Dohi
Yoshikata Misaki
Kazuhiko Yamamoto
Publication date
01-02-2008
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 1/2008
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-007-0002-3

Other articles of this Issue 1/2008

Modern Rheumatology 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.